

Disclosures

Personal Commercial (17)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|--|
| Self | | | |
| Amgen | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| argenx | Research/Research Grants ‡ <i>Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)</i> | Significant (>= \$5,000) | Other |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| CSL Behring | Consultant Fees/Honoraria | Modest (< \$5,000) | Arrhythmias and Clinical EP |
| Dexcom | Research/Research Grants | Modest (< \$5,000) | Prevention |
| Edwards | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Eli Lilly and Company | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Epirium Bio | Stock | Modest (< \$5,000) | Other |
| Esperion | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| jazz pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Medtronic | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Merck & Co., Inc. | Research/Research Grants | Modest (< \$5,000) | General Cardiology |
| Novartis Corporation | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Novartis Corporation | Research/Research Grants ‡ <i>Victorian-2 Prevent</i> | Significant (>= \$5,000) | General Cardiology |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Sanofi-Aventis | Consultant Fees/Honoraria | Modest (< \$5,000) | Arrhythmias and Clinical EP |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025

 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 12/16/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.